• September 9, 2016
  • 7:00 pm
  • California Institute of Integral Studies
    1453 Mission Street
    San Francisco, CA 94103
Add to Calendar 09/09/2016 7:00 pm 09/09/2016 America/Los_Angeles Psychedelics in Medicine and Psychiatry: An Experimental Treatment Model in Advanced-Stage Cancer and Existential Anxiety Psychedelics in Medicine and Psychiatry: An Experimental Treatment Model in Advanced-Stage Cancer and Existential Anxiety California Institute of Integral Studies
1453 Mission Street
San Francisco, CA 94103
false MM/DD/YYYY

Pre-registration - $15 
At the Door - $20
Members - $12

Buy Tickets

Over the past two decades there has been a resurgence of clinical research with hallucinogens. In particular, several studies have been approved in the United States and Europe exploring the clinical effects and therapeutic potential of psilocybin, the active alkaloid of hallucinogenic mushrooms. In this talk, Dr. Charles Grob reviews the ethnobotany, anthropology, chemistry, and toxicity of psilocybin, as well as the implications of the prior record of psychiatric investigations in this field. Within this context, Dr. Grob examines the hallucinogen treatment model with advanced-stage cancer patients with existential anxiety, including past and current research methodologies and outcomes. 

Charles S. Grob, MD, is Professor of Psychiatry and Pediatrics at the UCLA School of Medicine and the Director of the Division of Child and Adolescent Psychiatry at the Harbor-UCLA Medical Center. He has had a long-standing interest in the history of psychiatric research with hallucinogens, and has published in the medical and psychiatric literatures and presented talks at professional meetings in this area. Dr. Grob received the first FDA approval to carry out human research with 3,4-methylenedioxymethamphetamine (MDMA) in the early 1990s. He has also collaborated with Drs. Dennis McKenna and Jace Callaway on the Hoasca Project, a study designed to explore the biochemical, physiological, and psychological parameters of long-term ayahuasca use in Brazil. In 2004 Dr. Grob initiated an FDA approved research investigation examining the effects of psilocybin in advanced-stage cancer patients with severe anxiety, which was completed in 2008, and the results published in the Archives of General Psychiatry in 2011. He is currently conducting a pilot research study of an MDMA treatment model with autistic adults with social anxiety. He is a founding board member of the Heffter Research Institute. He is also the editor of Hallucinogens: A Reader, and the co-editor with Dr. Roger Walsh of Higher Wisdom: Eminent Elders Explore the Continuing Impact of Psychedelics.

This event is an educational program of the CIIS Center for Psychedelic Therapies and Research in collaboration with CIIS Public Programs & Performances.

Charles Grob

Stay Connected to CIIS